Muscarinic Antagonists

Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system.

Also Known As:

Networked: 2271 relevant articles (244 outcomes, 340 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Cazzola, Mario: 39 articles (07/2022 - 05/2009)
2.	Singh, Dave: 35 articles (02/2022 - 01/2012)
3.	Rogliani, Paola: 28 articles (07/2022 - 09/2011)
4.	Matera, Maria Gabriella: 24 articles (07/2022 - 02/2010)
5.	Andersson, Karl-Erik: 23 articles (10/2016 - 05/2002)
6.	Calzetta, Luigino: 22 articles (07/2022 - 05/2011)
7.	Donohue, James F: 20 articles (06/2021 - 04/2011)
8.	Buhl, Roland: 19 articles (05/2022 - 12/2010)
9.	Ferguson, Gary T: 19 articles (01/2021 - 12/2011)
10.	Kuo, Hann-Chorng: 18 articles (01/2022 - 06/2009)

Related Diseases

1.	Overactive Urinary Bladder (Overactive Bladder) 10/01/2011 - "Antimuscarinic drugs are still first-line treatment for the symptoms of overactive bladder (OAB) and are associated with good initial response rates. " 07/01/2009 - "Antimuscarinic drugs remain the first-line treatment of the overactive bladder and a favorable efficacy/tolerability-safety ratio can be confirmed. " 05/18/2016 - "Antimuscarinic agents are the mainstay of treatment for overactive bladder (OAB). " 01/01/2016 - "Antimuscarinic agents are the mainstay of treatment for overactive bladder (OAB). " 06/01/2012 - "Antimuscarinics, with or without an α-blocker, may be effective for the treatment of the storage symptoms of overactive bladder in some men. "
2.	Chronic Obstructive Pulmonary Disease (COPD) 01/01/2015 - "Aclidinium is a novel long-acting muscarinic antagonist with a good safety profile for the treatment of COPD, and has proven efficacy in both objective functional measurements and PROs. " 10/06/2023 - "In patients with symptomatic COPD receiving high-dose ICS/LABA, adding a long-acting muscarinic antagonist while decreasing the ICS dose by switching to medium-dose extrafine BDP/FF/G was associated with improved airway indices, especially in the distal airways, together with improvements in respiratory health status. " 11/01/2014 - "UMEC is the newer long-acting antimuscarinic agent (LAMA) that has demonstrated significant improvement in lung function and improved the quality of life in moderate-to-severe COPD patients. " 07/01/2018 - "The Global Initiative for Chronic Obstructive Lung Disease strategy recommends the use of a combination of long-acting β₂-agonist/long-acting muscarinic antagonists (LABA/LAMA) as the first-line treatment option in the majority of symptomatic patients with COPD. " 01/01/2018 - "Long acting muscarinic antagonists (LAMA) are currently considered the therapeutic mainstay for patients with COPD and have been shown to improve clinical outcomes including symptoms, exercise capacity and airflow limitation. "
3.	Asthma (Bronchial Asthma) 05/01/2011 - "Pharmacologic data all indicated that antimuscarinic drugs should be highly effective in asthma but clinical results were mixed. " 01/01/2022 - "Long-acting muscarinic antagonists are effective in all asthma phenotypes and endotypes." 10/01/2022 - "The addition of long-acting antimuscarinic agents (LAMA) has been shown to improve different aspects of asthma control, including symptoms, lung functions, and probably exacerbations. " 01/01/2023 - "In this review, the history of antimuscarinic agents, their effectiveness and safety in line with randomized controlled trials, and real-life studies in asthma treatment will be discussed according to the current data." 07/01/2023 - "Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?"
4.	Urinary Incontinence 02/01/2007 - "To examine the continence ('dryness') rate as an outcome measure of the efficacy of antimuscarinic treatment, and to explore how changes in bladder diary duration, baseline severity of urinary incontinence (UI), and study population characteristics affected this outcome. " 12/01/2018 - "Antimuscarinic agents will continue to represent the current gold standard for the first-line pharmacological management of OAB and urgency urinary incontinence. " 11/01/2015 - "The variables affecting remaining cumulative probability of antimuscarinics were age, history of anti-incontinence surgery or vaginal surgery, and having stress predominant urinary incontinence on urodynamic study. " 01/01/2014 - "To our knowledge this is the first antimuscarinic study in a community based, significantly older, medically complex elderly population with urgency urinary incontinence. " 09/01/2010 - "The International Consultation on Incontinence has recommended behavioural interventions with the cautious addition and trial of antimuscarinic drugs for the treatment of urinary incontinence in frail elderly individuals or those already in a state of decline; these recommendations may also be useful for vulnerable individuals. "
5.	Nocturia 01/01/2023 - "Antimuscarinics and beta-3 agonists were significantly more effective than placebo across most outcomes, with beta-3 agonists being more effective at reducing nocturia episodes and antimuscarinics causing significantly higher adverse events. " 01/01/2016 - "GJG appears to be a safe and effective potential therapeutic alternative for patients with nocturia unresponsive to α1-blockers or antimuscarinic drugs. " 11/09/2019 - "Data supporting the efficacy of α-blockers, antimuscarinics, and surgical bladder outlet procedures in the treatment of nocturia remains limited. " 01/01/2022 - "For efficacy we recommend: UUI episodes, urgency and nocturia episodes; for safety: antimuscarinic adverse events, other adverse events and discontinuation rates; for QoL: OAB-q, PPBC and IIQ scores." 01/01/2018 - "The clinical aspects of efficacy focus on improvements in the daytime urinary frequency, nocturia, bladder capacity, the frequency of urgency, severity of urgency, number of incontinence episodes, OAB symptom score, and quality of life (QOL) score by antimuscarinic agents in patients with OAB. "

Related Drugs and Biologics

1.	Bronchodilator Agents (Bronchodilators)
2.	mirabegron
3.	Adrenal Cortex Hormones (Corticosteroids)
4.	Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
5.	Atropine
6.	Cholinergic Antagonists (Anticholinergics)
7.	Tiotropium Bromide (Spiriva)
8.	Solifenacin Succinate
9.	Muscarinic Antagonists
10.	Pirenzepine

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Nebulizers and Vaporizers (Inhaler)
4.	Injections
5.	Metered Dose Inhalers (Metered Dose Inhaler)